collection
MENU ▼
Read by QxMD icon Read
search

Linfomas

shared collection
13 papers 0 to 25 followers
https://www.readbyqxmd.com/read/26260306/phase-ii-study-of-hcvidd-ma-in-patients-with-newly-diagnosed-peripheral-t-cell-lymphoma
#1
Dai Chihara, Barbara Pro, Sanam Loghavi, Roberto N Miranda, L Jeffrey Medeiros, Michelle A Fanale, Fredrick B Hagemeister, Luis E Fayad, Jorge E Romaguera, Felipe Samaniego, Sattva S Neelapu, Anas Younes, Nathan H Fowler, M Alma Rodriguez, Michael Wang, Larry W Kwak, Peter McLaughlin, Nam H Dang, Yasuhiro Oki
A phase II study was performed to evaluate the efficacy of hyper-fractionated cyclophosphamide, vincristine, pegylated liposomal doxorubicin and dexamethasone alternating with methotrexate/cytarabine (HCVIDD/MA) in patients with newly diagnosed peripheral T-cell lymphoma (PTCL), excluding ALK-positive anaplastic large cell lymphoma. Fifty-three patients were enrolled. Treatment was planned for up to 8 cycles but only 9% of patients received more than 6 cycles due primarily to disease progression (n = 13) or prolonged thrombocytopenia (n = 12)...
November 2015: British Journal of Haematology
https://www.readbyqxmd.com/read/26123794/deregulated-jak-stat-signalling-in-lymphomagenesis-and-its-implications-for-the-development-of-new-targeted-therapies
#2
REVIEW
Linda M Scott, Maher K Gandhi
Gene expression profiling has implicated several intracellular signalling cascades, including the JAK/STAT pathway, in the pathogenesis of particular subtypes of lymphoma. In marked contrast to the situation in patients with either acute lymphoblastic leukaemia or a myeloproliferative neoplasm, JAK2 coding sequence mutations are rare in lymphoma patients with an activated JAK/STAT "signature". This is instead the consequence of mutational events that result in the increased expression of non-mutated JAK2; positively or negatively affect the activity of other components of the JAK/STAT pathway; or establish an autocrine signalling loop that drives JAK-mediated cytokine-independent proliferation...
November 2015: Blood Reviews
https://www.readbyqxmd.com/read/26103436/mantle-cell-lymphoma-2015-update-on-diagnosis-risk-stratification-and-clinical-management
#3
REVIEW
Julie M Vose
DISEASE OVERVIEW: Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a short remission duration to standard therapies and a median overall survival (OS) of 4-5 years. DIAGNOSIS: Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t (11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1...
August 2015: American Journal of Hematology
https://www.readbyqxmd.com/read/26232170/frontline-rituximab-cyclophosphamide-doxorubicin-and-prednisone-with-bortezomib-vr-cap-or-vincristine-r-chop-for-non-gcb-dlbcl
#4
RANDOMIZED CONTROLLED TRIAL
Fritz Offner, Olga Samoilova, Evgenii Osmanov, Hyeon-Seok Eom, Max S Topp, João Raposo, Viacheslav Pavlov, Deborah Ricci, Shalini Chaturvedi, Eugene Zhu, Helgi van de Velde, Christopher Enny, Aleksandra Rizo, Burhan Ferhanoglu
This phase 2 study evaluated whether substituting bortezomib for vincristine in frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy could improve efficacy in non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL), centrally confirmed by immunohistochemistry (Hans method). In total, 164 patients were randomized 1:1 to receive six 21-day cycles of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2), and doxorubicin 50 mg/m(2), all IV day 1, prednisone 100 mg/m(2) orally days 1-5, plus either bortezomib 1...
October 15, 2015: Blood
https://www.readbyqxmd.com/read/26195701/mechanisms-of-action-of-lenalidomide-in-b-cell-non-hodgkin-lymphoma
#5
REVIEW
John G Gribben, Nathan Fowler, Franck Morschhauser
Lenalidomide is an orally active immunomodulatory drug that has direct antineoplastic activity and indirect effects mediated through multiple types of immune cells found in the tumor microenvironment, including B, T, natural killer (NK), and dendritic cells. Recently, the E3 ubiquitin ligase cereblon was identified as a molecular target that may underlie the effects of lenalidomide on tumor cells, as well as on cells in the tumor microenvironment. Decreases in cereblon attenuate these effects and also confer resistance to lenalidomide...
September 1, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26256929/-successful-treatment-with-dose-adjusted-epoch-r-for-triple-hit-lymphoma-having-bcl2-bcl6-and-myc-translocations
#6
Akari Hashimoto, Akihito Fujimi, Yuji Kanisawa, Chisa Nakajima, Naotaka Hayasaka, Shota Yamada, Toshinori Okuda, Shinya Minami, Tomoaki Matsumoto, Takanori Shibata, Kota Hamaguchi, Yusuke Kamihara, Sari Iwasaki, Junji Kato
Double- and triple-hit lymphomas (DHL/THL), high-grade B-cell lymphomas with an extremely poor prognosis, are defined by a chromosomal breakpoint affecting the MYC/8q24 locus in combination with another recurrent breakpoint. The successful use of dose-adjusted (DA) EPOCH-R in patients with MYC-positive lymphoma and Burkitt lymphoma (BL) was recently reported. A 74-year-old man with acute renal dysfunction and hyperkalemia was transferred to our emergency center by ambulance. PET-CT revealed a left renal hilar mass enveloping the abdominal para-aortic domain and bladder and hydronephrosis...
July 2015: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/26198444/persistent-disparities-among-patients-with-t-cell-non-hodgkin-lymphomas-and-b-cell-diffuse-large-cell-lymphomas-over-40-years-a-seer-database-review
#7
Jennifer A Crozier, Taimur Sher, Dongyun Yang, Abhisek Swaika, James Foran, Radhika Ghosh, Han Tun, Gerardo Colon-Otero, Kevin Kelly, Asher Chanan-Khan, Sikander Ailawadhi
BACKGROUND: As of 2013, more than 550,000 people are living with non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS: We undertook a large Surveillance Epidemiology and End Results (SEER) based analysis to describe outcome disparities in different subgroups of aggressive T-cell and B-cell NHL patients, with a focus on various ethnicities. RESULTS: The final analysis included 7662 patients with T-cell and 84,910 with B-cell NHL. Survival analysis revealed that male sex and increasing age were independent predictors of worse overall survival (OS; P < ...
October 2015: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/26149884/diagnosis-and-treatment-of-primary-cns-lymphoma-in-immunocompetent-patients-guidelines-from-the-european-association-for-neuro-oncology
#8
REVIEW
Khê Hoang-Xuan, Eric Bessell, Jacoline Bromberg, Andreas F Hottinger, Matthias Preusser, Roberta Rudà, Uwe Schlegel, Tali Siegal, Carole Soussain, Ufuk Abacioglu, Nathalie Cassoux, Martina Deckert, Clemens M F Dirven, Andrés J M Ferreri, Francesc Graus, Roger Henriksson, Ulrich Herrlinger, Martin Taphoorn, Riccardo Soffietti, Michael Weller
The management of primary CNS lymphoma is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the very few controlled studies available. In 2013, the European Association of Neuro-Oncology created a multidisciplinary task force to establish evidence-based guidelines for immunocompetent adults with primary CNS lymphoma. In this Review, we present these guidelines, which provide consensus considerations and recommendations for diagnosis, assessment, staging, and treatment of primary CNS lymphoma...
July 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26270899/role-of-radiation-therapy-in-primary-mediastinal-large-b-cell-lymphoma-in-rituximab-era-a-us-population-based-analysis
#9
Smith Giri, Vijaya Raj Bhatt, Ranjan Pathak, R Gregory Bociek, Julie M Vose, James O Armitage
The use of radiation (RT) in primary mediastinal large B-cell lymphoma (PMBCL) may predispose young patients to the risk of cardiopulmonary toxicities and secondary malignancies. We used Surveillance, Epidemiology and End Results (SEER) 18 database to compare the overall survival (OS) differences among adult patients treated with and without RT after rituximab approval in the US. Multivariate analyses were performed using Cox proportional hazards regression to compare OS based on the use of RT while adjusting for age, year of diagnosis, race, stage and gender...
November 2015: American Journal of Hematology
https://www.readbyqxmd.com/read/26261253/treatment-selection-and-survival-outcomes-in-early-stage-diffuse-large-b-cell-lymphoma-do-we-still-need-consolidative-radiotherapy
#10
John A Vargo, Beant S Gill, Goundappa K Balasubramani, Sushil Beriwal
PURPOSE: The choice between chemotherapy alone and chemotherapy plus consolidative radiotherapy (RT) for diffuse large B-cell lymphoma (DLBCL) remains controversial. We aimed to define factors affecting treatment selection and the resulting survival outcomes. PATIENTS AND METHODS: Using the National Cancer Data Base, we identified 59,255 patients with stages I and II DLBCL treated with multiagent chemotherapy alone or chemotherapy plus consolidative RT between 1998 and 2012...
November 10, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26265987/rare-gastrointestinal-lymphomas-the-endoscopic-investigation
#11
REVIEW
Calogero Vetro, Giacomo Bonanno, Giorgio Giulietti, Alessandra Romano, Concetta Conticello, Annalisa Chiarenza, Paolo Spina, Francesco Coppolino, Rosario Cunsolo, Francesco Di Raimondo
Gastrointestinal lymphomas represent up to 10% of gastrointestinal malignancies and about one third of non-Hodgkin lymphomas. The most prominent histologies are mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma. However, the gastrointestinal tract can be the site of rarer lymphoma subtypes as a primary or secondary localization. Due to their rarity and the multifaceted histology, an endoscopic classification has not been validated yet. This review aims to analyze the endoscopic presentation of rare gastrointestinal lymphomas from disease diagnosis to follow-up, according to the involved site and lymphoma subtype...
August 10, 2015: World Journal of Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/17105812/the-revised-international-prognostic-index-r-ipi-is-a-better-predictor-of-outcome-than-the-standard-ipi-for-patients-with-diffuse-large-b-cell-lymphoma-treated-with-r-chop
#12
Laurie H Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J Savage, Tamara Shenkier, Judy Sutherland, Randy D Gascoyne, Joseph M Connors
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, with patients exhibiting a wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP)has led to a marked improvement in survival and has called into question the significance of previously recognized prognostic markers. Since randomized controlled trials of R-CHOP in DLBCL have included select subgroups of patients, the utility of the International Prognostic Index (IPI) has not been reassessed. We performed a retrospective analysis of patients with DLBCL treated with R-CHOP in the province of British Columbia to assess the value of the IPI in the era of immunochemotherapy...
March 1, 2007: Blood
https://www.readbyqxmd.com/read/8141877/a-predictive-model-for-aggressive-non-hodgkin-s-lymphoma-the-international-non-hodgkin-s-lymphoma-prognostic-factors-project
#13
MULTICENTER STUDY
(no author information available yet)
BACKGROUND: Although many patients with intermediate-grade or high-grade (aggressive) non-Hodgkin's lymphoma are cured by combination chemotherapy, the remainder are not cured and ultimately die of their disease. The Ann Arbor classification, used to determine the stage of this disease, does not consistently distinguish between patients with different long-term prognoses. This project was undertaken to develop a model for predicting outcome in patients with aggressive non-Hodgkin's lymphoma on the basis of the patients' clinical characteristics before treatment...
September 30, 1993: New England Journal of Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"